Patheon is considering buying unique drug delivery technologies to expand its development service capabilities.
In September Patheon highlighted investment in development services as part of its strategy to improve on “poor historical performance”. Patheon is focusing initially on building organically in the UK and San Francisco, California but is also looking at acquisitions.
“We continue to evaluate external options. That could offer us some unique capabilities that would take time and significant effort to build”, Mark Kontny, president, global pharmaceutical development services at Patheon, told Outsourcing-Pharma.
Kontny said a “unique drug delivery technology that had specific expertise required” could be a suitable acquisition but was “not at liberty to discuss” the topic any further.